Total Payments
$3.1M
2024 Payments
$378,376
Companies
57
Transactions
3,357
Medicare Patients
722
Medicare Billing
$487,255
Payment Breakdown by Category
Other$2.3M (73.7%)
Consulting$477,315 (15.2%)
Travel$259,938 (8.3%)
Food & Beverage$70,460 (2.2%)
Research$18,946 (0.6%)
Education$1,562 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 748 | 72.6% |
| Consulting Fee | $477,315 | 132 | 15.2% |
| Travel and Lodging | $259,938 | 787 | 8.3% |
| Food and Beverage | $70,460 | 1,654 | 2.2% |
| Honoraria | $31,934 | 13 | 1.0% |
| Unspecified | $18,946 | 8 | 0.6% |
| Grant | $4,000 | 2 | 0.1% |
| Education | $1,562 | 13 | 0.0% |
Payments by Type
General
$3.1M
3,349 transactions
Research
$18,946
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $961,571 | 854 | $0 (2024) |
| GENZYME CORPORATION | $614,744 | 587 | $0 (2024) |
| EMD Serono, Inc. | $574,077 | 600 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $197,137 | 270 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $142,005 | 65 | $0 (2024) |
| Genentech USA, Inc. | $114,169 | 125 | $0 (2024) |
| TG Therapeutics, Inc. | $112,696 | 81 | $0 (2024) |
| Celgene Corporation | $94,461 | 90 | $0 (2024) |
| Horizon Therapeutics plc | $91,783 | 120 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $74,501 | 89 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $378,376 | 296 | EMD Serono, Inc. ($140,295) |
| 2023 | $319,744 | 349 | Biogen, Inc. ($119,809) |
| 2022 | $388,279 | 402 | Biogen, Inc. ($108,745) |
| 2021 | $345,132 | 359 | Biogen, Inc. ($120,528) |
| 2020 | $236,410 | 231 | Biogen, Inc. ($121,505) |
| 2019 | $480,005 | 485 | Biogen, Inc. ($132,677) |
| 2018 | $505,095 | 553 | GENZYME CORPORATION ($162,440) |
| 2017 | $495,898 | 682 | GENZYME CORPORATION ($185,484) |
All Payment Transactions
3,357 individual payment records from CMS Open Payments — Page 1 of 135
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $134.99 | General |
| 12/26/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $137.91 | General |
| 12/23/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Neurology | ||||||
| 12/18/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,935.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,062.50 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/18/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Travel and Lodging | Cash or cash equivalent | $1,214.53 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/18/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $119.99 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $55.26 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $32.17 | General |
| 12/16/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/12/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $5.37 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 12/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $750.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $36.16 | General |
| 12/09/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/07/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 12/07/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $40.40 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $829.57 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $520.28 | General |
| Category: Neurology | ||||||
| 12/04/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $1,165.73 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) | GENZYME CORPORATION | $10,000 | 1 |
| Primary MS | Genentech, Inc. | $5,602 | 1 |
| Study of ocrelizumab in PPMS patients assessing upper limb function | Hoffmann-La Roche Limited | $2,500 | 1 |
| A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis | Hoffmann-La Roche Limited | $624.00 | 1 |
| Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Biogen, Inc. | $219.94 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 173 | 17,560 | $475,014 | $151,011 |
| 2022 | 6 | 179 | 14,364 | $394,110 | $130,768 |
| 2021 | 5 | 184 | 632 | $279,222 | $83,780 |
| 2020 | 6 | 186 | 14,804 | $395,396 | $121,696 |
Total Patients
722
Total Services
47,360
Medicare Billing
$487,255
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 11 | 16,900 | $169,000 | $68,294 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 120 | 464 | $216,688 | $63,297 | 29.2% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 15 | 74 | $48,100 | $11,406 | 23.7% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 15 | 74 | $14,874 | $5,271 | 35.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 48 | $26,352 | $2,744 | 10.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 116 | 414 | $193,338 | $58,735 | 30.4% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2022 | 11 | 13,800 | $138,000 | $54,871 | 39.8% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2022 | 13 | 62 | $40,300 | $9,898 | 24.6% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 13 | 62 | $12,462 | $4,672 | 37.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $8,606 | $2,227 | 25.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 13 | 13 | $1,404 | $365.36 | 26.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 131 | 468 | $217,983 | $66,957 | 30.7% |
| 64644 | Injection of chemical for destruction of nerve muscles on one arm or leg, 5 or more muscles | Office | 2021 | 14 | 58 | $37,234 | $9,205 | 24.7% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2021 | 15 | 59 | $11,745 | $4,610 | 39.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $7,944 | $2,014 | 25.3% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 12 | 35 | $4,315 | $995.18 | 23.1% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2020 | 12 | 14,250 | $142,500 | $56,335 | 39.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 123 | 406 | $188,064 | $47,860 | 25.4% |
| 64644 | Injection of chemical for destruction of nerve muscles on arm or leg, 5 or more muscles | Office | 2020 | 14 | 63 | $40,950 | $9,664 | 23.6% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2020 | 14 | 62 | $12,462 | $4,570 | 36.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $7,944 | $2,025 | 25.5% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 11 | 11 | $3,476 | $1,241 | 35.7% |
About Dr. Daniel Bandari, M.D
Dr. Daniel Bandari, M.D is a Neurology healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467482216.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Bandari, M.D has received a total of $3.1M in payments from pharmaceutical and medical device companies, with $378,376 received in 2024. These payments were reported across 3,357 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.3M).
As a Medicare-enrolled provider, Bandari has provided services to 722 Medicare beneficiaries, totaling 47,360 services with total Medicare billing of $487,255. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Newport Beach, CA
- Active Since 07/04/2006
- Last Updated 11/29/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1467482216
Products in Payments
- AUBAGIO (Drug) $368,025
- VUMERITY (Drug) $270,183
- TYSABRI (Biological) $253,128
- Mavenclad (Drug) $244,559
- TECFIDERA (Drug) $233,666
- COPAXONE (Drug) $194,668
- ZEPOSIA (Drug) $186,809
- LEMTRADA (Drug) $181,616
- Rebif (Biological) $131,899
- BRIUMVI (Drug) $105,656
- UPLIZNA (Drug) $91,783
- OCREVUS (Biological) $86,496
- Mavenclad (Biological) $57,044
- MAVENCLAD (Drug) $47,998
- Ozanimod (Drug) $44,663
- PONVORY (Drug) $38,704
- SOLIRIS (Drug) $37,511
- Ponvory (Drug) $32,114
- Ocrevus (Biological) $25,977
- Tysabri (Biological) $23,829
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Newport Beach
Dr. Christopher O'carroll, M.d, M.D
Neurology — Payments: $1.1M
Neurology $1.1M
Neal Hermanowicz, Md, MD
Neurology — Payments: $889,095
Neurology $889,095
Dr. Yasir Jassam, Mbchb Mrcp(Uk), MBCHB MRCP(UK)
Neurology — Payments: $204,860
Neurology $204,860
Dr. Nita Chen, Md, MD
Neurology — Payments: $142,600
Neurology $142,600
Shawn Zardouz, Md, MD
Neurology — Payments: $60,444
Neurology $60,444
Dr. James Park, D.o, D.O
Neurology — Payments: $22,473
Neurology $22,473